+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Retigabine"

From
From
Antiepileptic Drugs Market - Forecast (2022 - 2027) - Product Thumbnail Image

Antiepileptic Drugs Market - Forecast (2022 - 2027)

  • Report
  • January 2022
  • 137 Pages
  • Global
From
The Treatment of Epilepsy. 3rd Edition - Product Thumbnail Image

The Treatment of Epilepsy. 3rd Edition

  • Book
  • July 2009
  • 1116 Pages
  • 6 Results (Page 1 of 1)
Loading Indicator

Retigabine is a drug used to treat epilepsy, a neurological disorder characterized by recurrent seizures. It is a potassium channel opener, meaning it works by increasing the activity of potassium channels in the brain, which helps to reduce the frequency of seizures. Retigabine is classified as an antiepileptic drug, and is part of a larger class of drugs known as Central Nervous System (CNS) drugs. These drugs are used to treat a variety of neurological disorders, including epilepsy, Parkinson's disease, and Alzheimer's disease. Retigabine is approved for use in the United States, Europe, and other countries. It is available in both oral and intravenous formulations. The drug is typically prescribed as an add-on therapy for patients who have not responded to other antiepileptic drugs. Some companies in the Retigabine market include GlaxoSmithKline, Eisai, and Lundbeck. Show Less Read more